Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).



Scope of the Report:

This report focuses on the CINV Existing and Pipeline Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for CINV Existing and Pipeline Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.



Market Segment by Manufacturers, this report covers

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro



Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



Market Segment by Type, covers

Aloxi (palonosetron)

Zofran Generic (ondansetron)

Kytril Generic (granisetron)

Emend (aprepitant)

Akynzeo (netupitant-palonosetron)

SUSTOL (extended release granisetron injection)

Rolapitant



Market Segment by Applications, can be divided into

Hospitals

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Drugstores



There are 15 Chapters to deeply display the global CINV Existing and Pipeline Drugs market.

Chapter 1, to describe CINV Existing and Pipeline Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of CINV Existing and Pipeline Drugs, with sales, revenue, and price of CINV Existing and Pipeline Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of CINV Existing and Pipeline Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source